% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • insmhistorian insmhistorian Jul 23, 2014 2:52 PM Flag

    I'm sorry...... post about my thoughts on Insmed/Roche/PUMA was deleted twice today. Since there must not be anything of interest there, I apologize for wasting the space of this board. Hope everyone is doing well.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Do you mean this one?

      -- Dave


      This is a little off-topic from Arikayce, but it is something that made me think.
      With all of the talk about PUMA yesterday/today, I read terms like breast cancer,
      Roche, Herceptin, and it got things rolling around my head. So, I looked
      back into the Insmed archives and found the following information from 2003.
      As much as I dislike Roche/Genentech (LOL) might they be interested in
      relationship with Insmed (separate from iPlex)).....again, LOL

      RICHMOND, Va.--(BUSINESS WIRE)--Dec. 3, 2003--Insmed Incorporated (Nasdaq-NMS: INSM) (Nasdaq: INSM) reported today that data from recent studies of the Company's proprietary anti-cancer compound, recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3), will be presented at The 26th Annual San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzalez Convention Center, San Antonio, Texas, December 3 - 6.

      These studies conducted in the laboratory of Dr. Brian Leyland-Jones of McGill University were designed to explore the ability of rhIGFBP-3 to sensitize breast cancer cells to Herceptin® (Trastuzumab).

      The results of this study, published in the abstract titled, "Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3) as a potential therapeutic agent for the treatment of Herceptin-resistant breast cancer", demonstrated the following:

      1. In Herceptin resistant breast carcinoma cells there was an increased level of insulin-like growth factor receptor.

      2. rhIGFBP-3 caused dose dependent inhibition of Herceptin resistant breast carcinoma growth.

      3. rhIGFBP-3 in combination with Herceptin caused a dose dependent increase in sensitivity of breast carcinoma cells to Herceptin.

      For reprints, please contact, Baxter Phillips, at 804.565.3041 or bphillips@insmed.c

    • That tells me that they`ll have to pry my shares out of my cold dead hands,because they`re not for sale until we see the 300.00 level at a minimum.

      Sentiment: Strong Buy

13.22+0.32(+2.48%)Aug 26 4:00 PMEDT